Denali Therapeutics Inc (NAS:DNLI)
$ 19.21 -0.05 (-0.26%) Market Cap: 2.74 Bil Enterprise Value: 1.86 Bil PE Ratio: 0 PB Ratio: 1.89 GF Score: 56/100

Denali Therapeutics Inc to Present Phase 1/2 Study of DNL310 Presentation Transcript

Jul 25, 2021 / 03:30PM GMT
Laura Hansen
Denali Therapeutics Inc. - VP of IR

Presentation
Jul 25, 2021 / 03:30PM GMT

=====================
Corporate Participants
=====================
* Carole Ho
Denali Therapeutics Inc. - Chief Medical Officer & Head of Development
* Laura Hansen
Denali Therapeutics Inc. - VP of IR
* Ryan J. Watts
Denali Therapeutics Inc. - Co-Founder, President, CEO & Director

=====================
-

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot